These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing, reported early 2004-000483-27 Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial. not-yet-due
Completed, but no date, and reported results 2004-000766-12 Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial bad-data
Reported results 2004-001748-66 Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo, en grupos paralelos, de la eficacia y seguridad de BIA 2-093 como tratamiento complementario en las crisis parciales re... 2008-01-22 due-trials
Ongoing 2004-004317-42 Ensayo clínico aleatorizado, doble ciego, doble dummy, controlado con placebo, para valorar la eficacia y seguridad de diferentes presentaciones de inmunoterapia subcutánea en pacientes asmáticos sens... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-002131-27 Efficacy and safety of eslicarbazepine acetate (BIA 2-093) in acute manic episodes associated with bipolar I disorder in a double-blind, randomised, dose-titration, placebo-controlled, multicenter cli... 2007-01-12 bad-data
Ongoing, reported early 2005-002133-13 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN A DOUBLE-BLIND, FIXED MULTIPLE DOSE, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTR... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-002134-35 EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER 2007-07-19 bad-data
Reported results 2006-001793-24 A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON T... 2007-09-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-001887-55 Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children: a double-blind, randomised, placebo-controlled, parallel-group, multicentr... 2017-08-24 bad-data
Reported results 2007-002461-12 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS THERAPY FOR PATIENTS WITH PAINFUL DIABETIC NEUROPATHY: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI... 2010-03-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-002473-31 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS THERAPY FOR PATIENTS WITH POST-HERPETIC NEURALGIA: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENT... 2010-05-19 bad-data
Ongoing, reported early 2008-002455-25 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL‑GROUP, MULTICENTR... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-003557-32 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE AS THERAPY IN PATIENTS WITH FIBROMYALGIA: A DOUBLE BLIND, RANDOMISED, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINICAL TRIAL 2010-09-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-003736-38 Efficacy and safety of Eslicarbazepine acetate as preventive therapy for patients with migraine: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial 2010-06-14 bad-data
Reported results 2008-003869-72 A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE... 2010-02-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-005606-39 Effects of Eslicarbazepine acetate (BIA 2-093) on cognitive function in children with partial onset seizures: an add-on, double-blind, randomised, palcebo-controlled, parallel-group, multicenter clini... 2015-04-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-011135-13 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI... 2016-09-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-012587-14 SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS 2013-10-08 bad-data
Reported results 2009-012897-12 A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltra... 2010-06-24 due-trials
Reported results 2010-019100-23 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain 2012-04-24 due-trials
Reported results 2010-019101-42 A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia 2012-04-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-021860-13 EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED,... 2014-12-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-022366-27 Efficacy and safety of BIA 9-1067 in idiopathic Parkinson’s disease patients with “wearing-off” phenomenon treated with levodopa plus a dopa decarboxylase inhibitor (DDCI): a double-blind, randomised,... 2013-06-13 bad-data
Not reported 2011-000814-21 A phase II, multicentre, randomized, double-blind study with subcutaneous immunotherapy at different doses, in parallel groups and placebo controlled in patients with rhinoconjunctivitis ± asthma sens... 2013-04-22 due-trials
Ongoing 2011-004583-30 A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVI... not-yet-due
Exempt 2012-000672-42 Biological standardization of allergen extracts of pollen of Artemisa vulgaris and Platanus acerifolia and the acarus Dermatophagoides farinae in patients sensitized to them. not-yet-due
Ongoing 2012-001091-11 OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZ... not-yet-due
Reported results 2012-003137-41 DOUBLE-BLIND STUDY IN PAEDIATRIC EPILEPTIC SUBJECTS AGED FROM 5 TO LESS THAN 8 YEARS TO COMPARE THE SUBJECT PREFERENCE FOR ESL SUSPENSION FORMULATION WITH ALTERNATIVE FLAVOURS 2012-12-31 due-trials
Not reported 2014-001459-22 OPEN CLINICAL TRIAL, MULTICENTER, WITH SUBCUTANEOUS IMMUNOTHERAPY IN DEPOT PRESENTATION, IN PATIENTS WITH ALLERGY RHINOCONJUNCTIVITIS SENSITIZED TO PARIETARIA JUDAICA 2016-03-11 due-trials
Completed, but no date 2014-001569-29 Phase II, multicenter, randomized, double-blind study, with subcutaneous immunotherapy in depot presentation, in parallel groups and placebo-controlled, in patients with rhinoconjunctivitis ± asthma s... bad-data
Listed as ongoing, but also has a completion date 2015-001243-36 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI... 2018-09-11 bad-data
Ongoing 2016-001072-29 OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZ... not-yet-due
Listed as ongoing, but also has a completion date 2016-002391-27 Efficacy and safety of opicapone in clinical practice in Parkinson’s Disease patients with wearing-off motor fluctuations 2018-07-04 bad-data
Not reported Terminated 2016-002944-18 MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC RHIN... 2017-04-10 due-trials
Ongoing 2018-002448-10 An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH) not-yet-due